Pal, S. K., Albiges, L., Bex, A., Suarez, C., Uzzo, R., Tang, X., Dubey, S., Goluboff, E. T., Carter, C. A., Xu, W., Banchereau, R., Huseni, M. A., Rini, B. I. (2025). Genomic characterization of baseline and post-progression tumors in IMmotion010, a randomized, phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with high-risk localized renal cell carcinoma (RCC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4510